INS and early-onset autosomal dominant Alzheimer disease: The use of intranasally administered insulin for the treatment of patients with Alzheimer’s disease and mild cognitive deficits leads to a significant improvement in their cognitive functions (see, for example, [15,16,17,18,19]).